Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor

Neoplasia

Volumn 13, Issue 3, 2011, Pages 266-275

  Tseng, Jeffrey R ^a   Stuart, Darrin ^b   Aardalen, Kimberly ^b   Kaplan, Angelo ^b   Aziz, Natasha ^b   Hughes, Nicholas P ^a   Gambhir, Sanjiv S ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHIR 265; FLUORODEOXYGLUCOSE F 18; GLUCOSE; LIPOCORTIN 5; THYMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG UPTAKE; GENE CONTROL; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; THYMIDINE METABOLISM; TUMOR XENOGRAFT;

EID: 79952393631     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101466     Document Type: Article

References (45)

1. Stuart D, Aardalen K, Venetsanakos E, Nagel T, Wallroth M, Batt D, Ramurthy S, Poon D, Faure M, Lorenzana E, et al. (2008). RAF265 is a potent Raf kinase inhibitor with selective anti-proliferative activity in vitro and in vivo. AACR Meeting Abstracts 2008, 4876.
2. Dhomen N and Marais R (2009). BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23, 529-545.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, and Phelps ME (2001). A tabulated summary of the FDG PET literature. J Nucl Med 42, 1S-93S.
4. Cherry SR, Shao Y, Silverman RW, Meadors K, Young J, Jones WF, Newport D, Mooyers C, Mumcuoglu EU, Chatziioannou A, et al. (1997). MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci 44, 1161-1166.
5. Pomper MG (2002). Can small animal imaging accelerate drug development? J Cell Biochem Suppl 39, 211-220.
6. Maclean D, Northrop JP, Padgett HC, and Walsh JC (2003). Drugs and probes: the symbiotic relationship between pharmaceutical discovery and imaging science. Mol Imaging Biol 5, 304-311.
7. Aboagye EO (2005). Positron emission tomography imaging of small animals in anticancer drug development. Mol Imaging Biol 7, 53-58.
8. Hargreaves RJ (2008). The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 83, 349-353.
9. Willmann JK, van Bruggen N, Dinkelborg LM, and Gambhir SS (2008). Molecular imaging in drug development. Nat Rev Drug Discov 7, 591-607.
10. Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, and Welch MJ (2002). MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 29, 783-790.
11. Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, and Thomas DM (2005). An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65, 9633-9636.
12. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, and Conti PS (2005). Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 4, 91-97.
13. Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, and Gambhir SS (2008). Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 49, 129-134.
14. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63, 3791-3798.
15. 18-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 45, 1754-1758.
16. 18 fluorothymidine PET. J Nucl Med 46, 114-120.
17. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65, 4202-4210.
18. Tseng JR, Dandekar M, Subbarayan M, Cheng Z, Park JM, Louie S, and Gambhir SS (2005). Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPETstudies in tumor xenografts in mice. J Nucl Med 46, 1851-1857.
19. Dandekar M, Tseng JR, and Gambhir SS (2007). Reproducibility of 2'-deoxy-2'-18F fluoro-D-glucose microPETstudies in mouse tumor xenografts. J Nuc Med 48, 602-607.
20. Sotiriou C and Piccart MJ (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7, 545-553.
21. Fehrmann RS, Li XY, van der Zee AG, de Jong S, Te Meerman GJ, de Vries EG, and Crijns AP (2007). Profiling studies in ovarian cancer: a review. Oncologist 12, 960-966.
22. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, and Thiesen HJ (2004). 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 45, 1528-1535.
23. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN, et al. (2004). Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31, 1621-1630.
24. Grigsby PW, Watson M, Powell MA, Zhang Z, and Rader JS (2006). Gene expression patterns in advanced human cervical cancer. Int J Gynecol Cancer 16, 562-567.
25. Strauss LG, Pan L, Koczan D, Klippel S, Mikolajczyk K, Burger C, Haberkorn U, Schönleben K, Thiesen HJ, and Dimitrakopoulou-Strauss A (2007). Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging 26, 804-812.
26. Erdem NF, Carlson ER, and Gerard DA (2008). Characterization of gene expression profiles of 3 different human oral squamous cell carcinoma cell lines with different invasion and metastatic capacities. J Oral Maxillofac Surg 66, 918-927.
27. von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, Schumacher U, Peldschus K, Adam G, Pilarsky C, et al. (2008). Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 49, 1362-1370.
28. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al. (2003). PGC-1a- responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267-273.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550.
30. Szustakowski JD, Lee J-H, Marrese CA, Kosinski PA, Nirmala NR, and Kemp DM (2006). Identification of novel pathway regulation during myogenic differentiation. Genomics 87, 129-138.
31. Storey JD and Tibshirani R (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100, 9440-9445.
32. Hoffman EJ, Huang SC, and Phelps ME (1979). Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3, 299-308.
33. Loening AM and Gambhir SS (2003). AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2, 131-137.
34. Stuart D, Kimberly A, Lorenzana EG, Salangsang FD, Venetsanakos E, Tan N, Zhang W, Garrett E, Jallal B, and Mendel DB (2006). Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf. AACR Meeting Abstracts 2006, 4856.
35. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, et al. (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11, 2785-2808.
36. Avril NE and Weber WA (2005). Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43, 189-204.
37. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, and Fisher S (1991). 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67, 1544-1550.
38. Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, and Lynch K (2005). Multi-centre phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs 23, 253-256.
39. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363, 809-819.
40. Parulekar WR and Eisenhauer EA (2004). Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96, 990-997.
41. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, and Moser E (2005). Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDGPET? Ann Oncol 16, 1524-1529.
42. Koh DM and Collins DJ (2007). Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188, 1622-1635.
43. Gambhir SS (2002). Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2, 683-693.
44. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, et al. (2005). The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11, 7967-7985.
45. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, et al. (2007). Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25, 675-680.